Shares of PROCEPT BioRobotics (NASDAQ: PRCT) tumbled 5.20% in pre-market trading on Wednesday, following the release of the company's third-quarter earnings report and 2026 revenue guidance. The surgical robotics company's stock price decline comes despite beating analyst expectations for Q3, as investors appear concerned about the company's future growth trajectory.

PROCEPT BioRobotics reported strong Q3 results, with revenue of $83.3 million surpassing the analyst estimate of $80.9 million. The company's adjusted EBITDA loss of $7.4 million also outperformed expectations, coming in better than the anticipated loss of $10.2 million. However, these positive results were overshadowed by the company's forward-looking projections.

While PROCEPT BioRobotics maintained its fiscal year 2025 revenue guidance of approximately $325.5 million, representing a 45% year-over-year growth, it was the newly issued fiscal year 2026 revenue guidance that disappointed investors. The company projects 2026 revenue to be in the range of $410 million to $430 million, indicating a growth rate of 26% to 32% compared to the 2025 guidance. This potential deceleration in growth appears to be the primary factor behind the stock's sharp pre-market decline, as investors had likely anticipated more aggressive growth projections for the coming year.